Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Bupranolol Action Pathway
Homo sapiens
Drug Action Pathway
Bupranolol is a nonselective beta-blocker with structural similarity to propanolol. Both drugs do not have intrinsic sympathomimetic activity. It competes with catecholamines for binding beta-1 adrenergic receptors in the heart to inhibit sympathetic activation. This inhibition causes decreased heart rate, cardiac output, blood pressure
References
Bupranolol Pathway References
Dinnendahl, V, Fricke, U. Arzneistoff-Profile (in German) 2 (21 ed.) (2007). Eschborn, Germany: Govi Pharmazeutischer Verlag.
Martin LJ, Piltonen MH, Gauthier J, Convertino M, Acland EL, Dokholyan NV, Mogil JS, Diatchenko L, Maixner W: Differences in the Antinociceptive Effects and Binding Properties of Propranolol and Bupranolol Enantiomers. J Pain. 2015 Dec;16(12):1321-1333. doi: 10.1016/j.jpain.2015.09.004. Epub 2015 Oct 9.
Pubmed: 26456674
Striated Muscle Contraction References
Cooke R: The sliding filament model: 1972-2004. J Gen Physiol. 2004 Jun;123(6):643-56. doi: 10.1085/jgp.200409089.
Pubmed: 15173218
Szent-Gyorgyi A: The mechanism of muscle contraction. Proc Natl Acad Sci U S A. 1974 Sep;71(9):3343-4.
Pubmed: 4610574
Kuo IY, Ehrlich BE: Signaling in muscle contraction. Cold Spring Harb Perspect Biol. 2015 Feb 2;7(2):a006023. doi: 10.1101/cshperspect.a006023.
Pubmed: 25646377
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Settings